DGX SVP now holds 8,379 direct shares after 15-share acquisition
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Quest Diagnostics (DGX): A company officer reported an insider transaction on a Form 4. On 10/21/2025, the SVP, Clinical Solutions acquired 15 shares of common stock at $189.076 per share.
Following this transaction, the reporting person beneficially owns 8,379 shares directly, plus 358 shares indirectly through a trust and 1,635 shares indirectly via the Company’s 401(k) plan.
Per the footnotes, the 15 shares were acquired through a dividend reinvestment plan and are eligible for deferred reporting on Form 5 under Rule 16a-6; the reporting person chose to report them early.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
KUPPUSAMY KARTHIK
Role
SVP, Clinical Solutions
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 15 | $189.076 | $3K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 8,379 shares (Direct);
Common Stock — 358 shares (Indirect, By Trust)
Footnotes (1)
- Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. The amount includes exempt purchases made under the Company's stock purchase plan since the date of the reporting person's last filing on Form 4. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.